Immunosuppression for islet transplantation.

Hirofumi Noguchi, Shinichi Matsumoto, Masayuki Matsushita, Naoya Kobayashi, Kōichi Tanaka, Hideki Matsui, Noriaki TanakaPubMed 2006 · DOI

Abstract

The development by the Edmonton group of a sirolimus-based, steroid-free, low-tacrolimus regimen is a significant breakthrough that allows the rate of insulin independence after islet transplantation to increase from 13% to 80% at 1 year; however, the rate is reduced to 50% at 3 years, attributed to prolonged tacrolimus exposure. Recently, immunosuppression agents such as cyclosporine, mycophenolate mofetil, and the novel agent FTY 720 have been used instead of tacrolimus. Lymphocyte-depleting antibodies such as anti-thymocyte globulin, alemtuzumab, and hOKT3gamma 1 (ala, ala) have been launched, and a costimulatory blockade of anti-CD40 monoclonal antibodies and CTLA4-Ig will be attempted in the near future. Moreover, the potential of a novel immunosuppressing peptide could now be realized using new technology called the protein transduction system. In this review, we show some of the most recent contributions to the advancement of knowledge in this field.
BibTeX
@inproceedings{noguchi2006immunosuppression,
  author = {Hirofumi Noguchi and Shinichi Matsumoto and Masayuki Matsushita and Naoya Kobayashi and Kōichi Tanaka and Hideki Matsui and Noriaki Tanaka},
  title = {{Immunosuppression for islet transplantation.}},
  booktitle = {PubMed},
  year = {2006},
  doi = {10.18926/amo/30733},
}

Loading related content...

Figure